Silence Therapeutics (SLN) News Today → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Buy SLN with Qtrade Free SLN Stock Alerts $22.09 +0.18 (+0.82%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 26 at 3:20 AM | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Rating Reiterated by HC WainwrightMay 24, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday.May 23, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Trading Down 7.4%Silence Therapeutics (NASDAQ:SLN) Stock Price Down 7.4%May 21, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Trading Up 4.4%Silence Therapeutics (NASDAQ:SLN) Trading Up 4.4%May 19, 2024 | americanbankingnews.comSilence Therapeutics' (SLN) "Buy" Rating Reaffirmed at Chardan CapitalMay 19, 2024 | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Receives "Buy" Rating from HC WainwrightMay 17, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday.May 17, 2024 | markets.businessinsider.comWhat 7 Analyst Ratings Have To Say About Silence TherapeuticsMay 16, 2024 | investorplace.comSLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024May 16, 2024 | businesswire.comSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressMay 11, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Sees Large Growth in Short InterestSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 297,200 shares, an increase of 104.0% from the April 15th total of 145,700 shares. Based on an average daily volume of 228,000 shares, the short-interest ratio is presently 1.3 days.May 9, 2024 | marketbeat.comVivo Capital LLC Invests $8.86 Million in Silence Therapeutics plc (NASDAQ:SLN)Vivo Capital LLC bought a new position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 510,204 shares of the company's stock, valued atApril 30, 2024 | businesswire.comSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceApril 29, 2024 | businesswire.comSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsApril 27, 2024 | marketbeat.comVivo Capital LLC Buys 595,250 Shares of Silence Therapeutics plc (NASDAQ:SLN)Vivo Capital LLC lifted its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 116.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,105,454 shares of the company's stock after purchasing an additional 595,250 shares during the period.April 22, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives Overweight Rating from Morgan StanleyMorgan Stanley reissued an "overweight" rating and issued a $45.00 price objective on shares of Silence Therapeutics in a research report on Monday.April 16, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Trading Up 3.2%Silence Therapeutics (NASDAQ:SLN) Trading Up 3.2%April 13, 2024 | yahoo.comA youth's call to action on this Day of NO SilenceApril 12, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest UpdateSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 162,000 shares, a growth of 74.8% from the March 15th total of 92,700 shares. Based on an average daily volume of 241,700 shares, the days-to-cover ratio is currently 0.7 days.April 11, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeSilence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeApril 11, 2024 | investorplace.com3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024April 9, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Stock Price Down 4.5%Silence Therapeutics (NASDAQ:SLN) Shares Down 4.5%April 8, 2024 | businesswire.comSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)April 1, 2024 | yahoo.comThe Lady of Silence: The Mataviejitas Murders Streaming: Watch & Stream Online via NetflixMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 18, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Price Target Raised to $42.00 at Chardan CapitalChardan Capital upped their target price on Silence Therapeutics from $26.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday.March 18, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Shares Gap Up to $22.84Silence Therapeutics (NASDAQ:SLN) Shares Gap Up to $22.84March 16, 2024 | finance.yahoo.comAnalysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest ResultsMarch 15, 2024 | seekingalpha.comSilence Therapeutics plc (SLN) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Stock Price Down 5.5%Silence Therapeutics (NASDAQ:SLN) Trading Down 5.5%March 15, 2024 | finance.yahoo.comSilence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Hits New 12-Month High at $27.72Silence Therapeutics (NASDAQ:SLN) Hits New 52-Week High at $27.72March 13, 2024 | yahoo.comLocal authors 'Break the Silence' with book anthology to share the stories of survivorsMarch 13, 2024 | sg.finance.yahoo.comSingTel looking to sell significant Optus stake to Brookfield - sourceMarch 13, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Shares Gap Down to $25.90Silence Therapeutics (NASDAQ:SLN) Shares Gap Down to $25.90March 13, 2024 | seekingalpha.comSilence Therapeutics plc 2023 Q4 - Results - Earnings Call PresentationMarch 13, 2024 | businesswire.comSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 13, 2024 | businesswire.comSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)March 12, 2024 | markets.businessinsider.comSilence Therapeutics earnings: here's what Wall Street expectsMarch 5, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sets New 12-Month High at $26.74Silence Therapeutics (NASDAQ:SLN) Sets New 52-Week High at $26.74February 28, 2024 | finance.yahoo.comSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024February 28, 2024 | businesswire.comSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024February 24, 2024 | seekingalpha.comSilence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A LookFebruary 23, 2024 | businesswire.comSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and Aurinia Pharmaceuticals (AUPH)February 21, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sets New 52-Week High at $25.00Silence Therapeutics (NASDAQ:SLN) Hits New 12-Month High at $25.00February 16, 2024 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?February 12, 2024 | investing.comSilence Therapeutics PLC (SLN)February 5, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Shares Up 1.9%Silence Therapeutics (NASDAQ:SLN) Trading Up 1.9%February 5, 2024 | finance.yahoo.comSilence Therapeutics Announces Oversubscribed $120 Million Private Placement Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Digitizing the $11T commodities sector with one tiny stock (Ad)One tiny company — trading completely undiscovered around 15-cents per share — has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. It’s an opportunity that likely won’t stay at these levels for long SLN Media Mentions By Week SLN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLN News Sentiment▼0.620.92▲Average Medical News Sentiment SLN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLN Articles This Week▼71▲SLN Articles Average Week Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALXO News SAGE News CVAC News NUVB News PAHC News AVBP News LYEL News PRAX News IRON News PHVS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLN) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
